Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET

Praxis Precision Medicines, Inc. is upgraded to Strong Buy, driven by pipeline progress and positive Phase 3 data for ...

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the ...

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

The AES meeting is a cornerstone for the epilepsy community, bringing together science, clinical innovation, and patient advocacy,” said Steven Petrou, chief scientific officer and co-founder of ...

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
Yahoo Finance

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
Investing

Praxis study halted for futility, other programs advance

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
Stocktwits on MSN

Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position

Culper noted that the company went ahead with a late-stage trial despite an independent monitoring committee recommending ...
Hosted on MSN

Jefferies maintains Praxis stock with $305 target, bullish on catalysts

On Wednesday, Jefferies reaffirmed its positive stance on Praxis Precision Medicines Inc . (NASDAQ:PRAX), maintaining a Buy rating and a price target of $305.00. The stock, currently valued at $1.54 ...
Benzinga.com

Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate

On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...
Seeking Alpha

Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts

I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...
Yahoo Finance

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...